Surgery for metastatic cancer, often called metastasectomy or “mets surgery,” removes tumors that have spread from their original site to distant organs such as the liver, lungs, brain, bones, or adrenal glands. Once considered pointless because metastatic disease was thought to be uniformly incurable, surgical removal of metastases is now a standard part of cancer treatment for carefully selected patients, and in some scenarios it produces long-term survival that rivals what is seen after treatment of the original cancer itself. The approach is neither universally appropriate nor universally futile, and the specifics depend heavily on which organ harbors the spread, how many spots exist, and what the primary cancer is.
The Oligometastatic Idea That Changed Everything
For most of the twentieth century, oncologists drew a hard line between “localized” cancer and “metastatic” cancer. If it had spread, systemic drug therapy was the only realistic option. In 1995, researchers Samuel Hellman and Ralph Weichselbaum challenged that binary by proposing an intermediate state they called oligometastatic disease, a condition in which cancer has spread but only to a limited number of sites and could still potentially be cured with aggressive local treatment.1PubMed Central. Oligometastatic disease, the curative challenge in radiation oncology They described it as something between a purely localized tumor and widely scattered disease, and argued it was “amenable to a curative therapeutic strategy” using surgery or radiation.2Cancer Treatment Communications. Oligometastases: Defined by prognosis and evaluated by cure
That idea became the intellectual foundation for most modern metastasectomy. The practical threshold that surgeons use varies, but the general thinking is that patients with a small number of metastases, often in a single organ, who respond well to chemotherapy and whose primary cancer is controlled may benefit from surgical removal of those deposits. The goal in these cases is not just palliation but genuine long-term disease control or cure.
Liver Metastases From Colorectal Cancer
The liver is the proving ground for metastasectomy, and the evidence here is strongest. About half of people with colorectal cancer eventually develop liver metastases. Surgical resection offers the best chance for survival in this group, with five-year survival rates reaching up to about 58% in well-selected patients.3PubMed Central. Current treatment for colorectal liver metastases A single-center study from Iran reported a median overall survival of 43 months after liver resection for colorectal metastases, with estimated five-year survival around 42%.4BMC Surgery. Long-term survival after hepatic resection for colorectal liver metastases: a single-center study in Iran Those numbers matter because, without surgery, median survival for colorectal liver metastases treated with chemotherapy alone is typically well under two years.
Several factors predict how well someone does after liver metastasectomy. A prognostic study found that poorer outcomes were linked to age over 60, having many metastases, the largest lesion being over 5 cm, a right-sided primary tumor, and the presence of disease outside the liver.5PubMed. Prediction of survival in patients with colorectal liver metastases- development and validation of a prognostic score model In practice, this means the surgeon and oncologist weigh the number, size, and location of lesions alongside the patient’s overall health and how the cancer has responded to chemotherapy. A person with two small liver metastases who had a strong response to initial chemo is in a very different category than someone with a dozen large spots scattered across both liver lobes.
Not everyone with liver metastases is eligible for surgery right away. If the tumor burden is large, the remaining liver after surgery might be too small to function safely. A technique called portal vein embolization addresses this by blocking blood flow to the liver lobe that will be removed, stimulating the other lobe to grow larger before the operation. This approach has expanded eligibility and allowed patients who were once considered unresectable to undergo potentially curative surgery.6PubMed Central. Portal vein embolization effect on colorectal cancer liver metastasis progression: Lessons learned
When Chemotherapy Creates a Surgical Opportunity
Some patients present with liver or other metastases that surgeons cannot safely or completely remove at diagnosis. “Conversion therapy” refers to giving chemotherapy, often combined with a targeted drug, with the explicit goal of shrinking those metastases enough to allow resection. This is distinct from standard palliative chemotherapy, because the endpoint is getting into the operating room, not just buying time.
In colorectal liver metastases, combination chemotherapy regimens with bevacizumab or similar agents have achieved high tumor-shrinkage rates and meaningful resection rates.7PubMed Central. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents One study found that patients who underwent surgical resection after successful conversion lived significantly longer (median 20 months) than those in whom conversion failed (15 months).8PubMed Central. Conversion therapy combined with individualized surgical treatment strategy improves survival in patients with colorectal cancer liver metastases
The conversion concept is also gaining traction in hepatocellular carcinoma (primary liver cancer), where combinations of targeted drugs, immunotherapy, and locoregional treatments can shrink tumors enough for surgery. A meta-analysis found that the chances of successful conversion ranged from about 5% with some drug-only approaches to roughly a third when a targeted drug was combined with immunotherapy and locoregional treatment. Patients who made it to surgery had significantly better survival than those who stayed on systemic treatment alone.9PubMed Central. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Lung Metastasectomy
The lungs are another common landing spot for metastases, especially from colorectal cancer, sarcomas, and kidney cancer. Evidence here is less definitive than for liver surgery, largely because there have been very few randomized trials comparing lung metastasectomy to no surgery. Decisions tend to rest on decades of observational data and clinical experience rather than gold-standard trial results.
For colorectal cancer that spreads to the lungs, roughly 9 to 12% of patients with pulmonary metastases are candidates for treatment with curative intent, including surgery.10PubMed Central. Colorectal Cancer Pulmonary Metastasectomy: When, Why and How A population-based study using matched comparisons found that patients who underwent lung metastasectomy lived a median of 51 months versus 36 months for those who did not, and the surgery was an independent predictor of better survival.11Gastroenterology Report. Survival benefit of metastasectomy in colorectal cancer with pulmonary metastasis: a population-based, propensity score matched study Another study reported a median overall survival of 55 months after lung metastasectomy for colorectal cancer.12PubMed. Survival outcome of pulmonary metastasectomy among the patients with colorectal cancers
Sarcomas have a particular tendency to spread to the lungs, and chemotherapy alone offers only limited benefit for these metastases. Lung metastasectomy in selected sarcoma patients can lead to long-term survival, with five-year rates reported between 15% and about 50% depending on the specific tumor type and patient factors.13PubMed Central. Survival and prognostic factors following pulmonary metastasectomy for sarcoma Recurrence in the lungs is common after resection, but repeat operations are increasingly performed, with some patients undergoing multiple rounds of metastasectomy over the years as new spots appear.14PubMed Central. Management of Sarcoma Metastases to the Lung
Brain Metastases
Brain metastases present a different calculus. The brain is enclosed in a rigid skull, so even a modest tumor can compress critical structures and cause devastating symptoms. Surgery here serves a dual purpose: it removes the cancer and immediately relieves the pressure causing neurological problems.
One study found that neurological improvement occurred in about 57% of patients after surgical removal of brain metastases, with the best results in patients who had elevated intracranial pressure or weakness on one side of the body. The neurological benefits held regardless of how poor the patient’s overall prognosis was, and the complication rates from surgery were low.15PubMed Central. Surgical Resection of Brain Metastases—Impact on Neurological Outcome
A common question is whether surgery is better than stereotactic radiosurgery (focused radiation) for brain metastases. A meta-analysis comparing the two found no difference in two-year survival, though surgical patients had a higher risk of the tumor growing back at the same spot.16PubMed Central. Management of brain metastasis. Surgical resection versus stereotactic radiotherapy: a meta-analysis A Cochrane review concluded there is no definitive evidence that one approach is better than the other overall, and decisions should be made case by case.17Cochrane Database of Systematic Reviews. Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis In practice, surgery tends to be preferred for large lesions causing significant mass effect, while radiosurgery is favored for smaller, deeper, or multiple lesions.
Peritoneal Metastases and Heated Chemotherapy
When cancer spreads to the lining of the abdominal cavity (the peritoneum), it creates a particularly challenging scenario. The standard surgical approach combines cytoreductive surgery, where the surgeon strips away all visible tumor deposits from the peritoneal surfaces, with hyperthermic intraperitoneal chemotherapy (HIPEC), a technique in which heated chemotherapy is bathed directly inside the abdomen at the end of surgery.18PubMed Central. Cytoreductive Surgery and Peritonectomy Procedures For selected patients with colorectal peritoneal metastases, this combination has been linked to long-term survival and even cure in some cases.19PubMed Central. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer
However, the PRODIGE 7 trial shook up this field considerably. This large randomized trial found that adding HIPEC to cytoreductive surgery did not improve overall survival (median around 41-42 months in both groups) and was associated with more late complications.20The Lancet Oncology. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer (PRODIGE 7) The trial’s authors suggested that cytoreductive surgery itself, rather than the heated chemo wash, should be the cornerstone of curative strategies. This remains actively debated, and the role of HIPEC varies by cancer type and by center.
Bone and Spine Metastases
Bone metastases, particularly in the spine, are usually not treated with curative intent. The primary goals are pain control, preservation of mobility, and prevention of catastrophic fractures. But the stakes are high: a metastasis in the spine can compress the spinal cord and cause paralysis if untreated.
Timing turns out to matter a lot. In patients with acute spinal cord compression from metastases, those who underwent surgery within 16 hours had a significantly higher rate of neurological improvement at discharge (about 27%) compared to those operated after 16 hours (about 10%).21PubMed Central. Surgery in Acute Metastatic Spinal Cord Compression: Timing and Functional Outcome This makes metastatic spinal cord compression a genuine surgical emergency.
For long bones, there is strong evidence favoring prophylactic surgery, meaning stabilizing the bone before it actually breaks, rather than waiting for a fracture to happen. Patients who had their bone fixed before it fractured had a higher one-year survival rate (46% versus 38%), less blood loss during surgery, shorter anesthesia times, and fewer repeat operations.22Journal of Bone & Joint Surgery. Outcomes of Surgery for Impending Versus Completed Pathological Fracture in Cancer Patients It is also substantially cheaper: prophylactic stabilization cost on average about $21,000 less than fixing a completed fracture, partly because hospital stays were about four days shorter.23PubMed Central. Is Prophylactic Intervention More Cost-effective Than the Treatment of Pathologic Fractures in Metastatic Bone Disease?
Quality-of-life improvements after spine metastasis surgery are consistently reported. Studies have found significant improvements in walking ability, pain, general performance, and overall quality of life, and these gains were maintained over follow-up.24PubMed Central. Health-related quality of life after surgery for spinal metastases One prospective study of 118 patients found rapid improvement in pain, neurological deficits, and overall functioning after surgery, though the complication rate was 26% and twelve-month mortality was 48%, underscoring that these are sick patients being treated to preserve function rather than cure disease.25PubMed Central. Surgery improves pain, function and quality of life in patients with spinal metastases: a prospective study on 118 patients
An interesting finding from a multicenter study is that for patients whose main problem is spinal instability rather than severe neurological symptoms, simply stabilizing the spine may be enough. Adding a more aggressive decompression procedure did not show clear advantages in patients with only mild neurological symptoms, even when the spinal canal looked quite narrowed on imaging.26Scientific Reports. The significance of adding posterior decompression to spine stabilization in metastatic spinal surgery: a multicenter prospective study
Adrenal Metastases
The adrenal glands sit on top of the kidneys and are a recognized site of metastasis for lung cancer, melanoma, and kidney cancer. Removing a solitary adrenal metastasis is technically straightforward, and the evidence, though largely observational, suggests it can be worthwhile for carefully chosen patients. A study of lung cancer patients with solitary adrenal metastases concluded the operation was safe and that these patients should be considered surgical candidates.27PubMed. Adrenalectomy for solitary adrenal metastases from non-small cell lung cancer
In melanoma, where the adrenal gland is also a common metastatic target, the survival difference is striking in retrospective data. One study found that patients treated surgically lived a median of nearly 117 months after adrenal metastasis diagnosis versus only 11 months for those who did not undergo surgery, and adrenalectomy was one of the strongest factors associated with better outcomes even after adjusting for other variables.28Journal of Surgical Oncology. Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management The enormous gap likely reflects selection bias, since healthier patients with more favorable disease biology get offered surgery, but the finding reinforces that adrenalectomy belongs in the discussion for patients with limited metastatic melanoma.
Surgery for Kidney Cancer That Has Spread
Kidney cancer has a somewhat unique relationship with metastasectomy. For decades, removing the primary kidney tumor (cytoreductive nephrectomy) even after the cancer had already spread was standard practice, based on early trial data showing a survival benefit. Two more recent randomized trials, CARMENA and SURTIME, complicated this picture by questioning whether all patients with metastatic kidney cancer benefit from immediate removal of the kidney.29PubMed Central. Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma A large observational study using instrumental variable analysis similarly found no clear survival advantage for cytoreductive nephrectomy in the broad population of patients with metastatic clear cell kidney cancer, noting that much of the apparent benefit seen in simpler analyses was likely driven by unmeasured differences between patients who were offered surgery and those who were not.30JAMA Network Open. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
The picture shifted again with the arrival of modern immunotherapy. A database analysis found that patients who underwent cytoreductive nephrectomy alongside immune checkpoint inhibitor therapy had superior survival compared to immunotherapy alone.31PubMed Central. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era The current thinking is that some patients still benefit from upfront nephrectomy while others are better served by starting systemic therapy first and potentially having the kidney removed later if they respond well. Additionally, after targeted therapy shrinks metastatic deposits, consolidative metastasectomy can allow patients significant time off their drugs and sometimes produce long-term tumor-free status.32PubMed Central. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma
Oligoprogression and Saving Treatment Lines
One of the more practical applications of metastasectomy is in a scenario called oligoprogression. This is when most of a patient’s metastases are controlled by systemic therapy but one or two spots start growing again. Rather than switching the entire drug regimen, which means burning through a limited number of available treatment lines, surgeons can remove just the resistant lesion and allow the patient to continue on the same therapy. A study of kidney cancer patients with thoracic oligoprogression found that resecting the progressing spot delayed or avoided the need to change systemic therapy, effectively preserving future treatment options.33PubMed Central. Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies
Robotic and Minimally Invasive Techniques
Metastasectomy has followed the broader surgical trend toward less invasive approaches. Robotic and laparoscopic techniques are increasingly used for liver metastasectomy in particular. A meta-analysis comparing robotic versus laparoscopic liver resection for colorectal metastases found comparable safety and effectiveness, though the laparoscopic group had a higher conversion rate to open surgery (about 12%) compared to the robotic group (about 7%).34PubMed Central. Robotic versus Laparoscopic Liver Resections for Colorectal Metastases: A Systematic Review and Meta-Analysis A single-center series of robotic liver resections for colorectal metastases reported that all lesions were removed with clear margins, average hospital stays were under five days, and no local recurrences were seen during follow-up.35PubMed Central. Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience
Perhaps the most dramatic illustration of what robots can do is a reported case where a single robotic procedure removed a rectal cancer plus liver and lung metastases in one operation, sparing the patient from having three separate surgeries.36PubMed Central. Robot-assisted one-stage resection of rectal cancer with liver and lung metastases These combined procedures remain uncommon but illustrate the direction the field is heading.
How Circulating Tumor DNA May Sharpen Patient Selection
One of the persistent challenges in metastasectomy is figuring out who will actually benefit. Imaging and conventional blood markers miss a lot: some patients look like great candidates on scans but recur quickly, while others with worrying features do well. Circulating tumor DNA, tiny fragments of cancer DNA shed into the bloodstream, is being studied as a way to improve this selection process. A prospective study of patients undergoing liver metastasectomy for colorectal cancer found that measuring circulating tumor DNA before and after surgery could help stratify patients by their risk of recurrence.37PubMed Central. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases This type of “liquid biopsy” information could eventually guide decisions about whether to offer surgery, how aggressively to follow up afterward, and whether to add chemotherapy after the operation.
Palliative Surgery When Cure Is Not the Goal
Not all surgery for metastases aims for cure. Palliative metastasectomy focuses on symptom relief: clearing a bowel obstruction caused by peritoneal deposits, decompressing a spinal cord being crushed by tumor, or removing a brain lesion causing disabling symptoms. The goals here are shorter hospital stays, reduced pain, better mobility, and preserved independence. In cases like small bowel carcinomatosis causing obstruction, the primary objective of surgical intervention is symptom relief and quality-of-life improvement rather than pursuing curative intent.38Surgery, Gastroenterology and Oncology. Palliative Surgical Interventions in Small Bowel Carcinomatosis: Impact on Critical Care Outcomes The spine surgery quality-of-life data cited earlier reflects this same reality: even with 48% twelve-month mortality, most patients walked better and hurt less after surgery, which is the whole point when the clock is already running.